Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | FGF23 | Q9GZV9 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761174 | 1.00 | AMY1A (0.53) | AMY1AALDH1A1MAPTLMNAHPGD | |
| SCHEMBL3175343 | 1.00 | AMY1A (0.53) | AMY1AALDH1A1MAPTLMNAHPGD | |
| SCHEMBL11744250 | 0.82 | AMY1A (0.56) | AMY1AALDH1A1MAPTLMNAHPGD | |
| SCHEMBL10362380 | 0.81 | MAPT (0.49) | ALDH1A1MAPTLMNAHPGDFGF23 | |
| SCHEMBL17548942 | 0.81 | MAPT (0.49) | ALDH1A1MAPTLMNAHPGDFGF23 | |
| SCHEMBL4232054 | 0.81 | MAPT (0.53) | ALDH1A1MAPTLMNAHPGDFGF23 | |
| SCHEMBL19346343 | 0.80 | AMY1A (0.55) | AMY1AALDH1A1MAPTLMNAHPGD | |
| SCHEMBL17503145 | 0.79 | HPGD (0.43) | ALDH1A1MAPTLMNAHPGDFGF23 | |
| SCHEMBL17503146 | 0.79 | HPGD (0.43) | ALDH1A1MAPTLMNAHPGDFGF23 | |
| SCHEMBL2928826 | 0.79 | FGF23 (0.47) | ALDH1A1MAPTLMNAHPGDFGF23 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835660-B | Preparation method of oxime ether | 浙江理工大学 | 2024-03-22 | — | — | CN | claimed |
| CN-114835660-A | Preparation method of oxime ether | 浙江理工大学 | 2022-08-02 | — | — | CN | claimed |
| CN-114835660-B | Preparation method of oxime ether | 浙江理工大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-114835660-A | Preparation method of oxime ether | 浙江理工大学 | 2022-08-02 | — | — | CN | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| CN-101910160-B | Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1 | BIOVITRUM AB PUBL | 2013-01-09 | — | — | CN | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | AMY1A 4084/4885ALDH1A1 1996/4885MAPT 84/4885 |
| US-20100022590-A1 | Novel compounds | HSD11B1, CYP11B1, HSD11B2 | AMY1A 892/4885ALDH1A1 164/4885MAPT 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.